Filing Flows › Insulet (PODD) › Q2 2026 › vs Q2 2025
Insulet (PODD) Q2 2026 vs Q2 2025 (year over year)
Insulet's revenue rose $153M (+24%) from $649M in Q2 2025 to $802M in Q2 2026. The biggest changes: Total Omnipod products +$157M (+25%); Drug Delivery −$4.4M (-43%). Gross margin 70.2% against 69.7% (+0.5 pts).
Insulet, Q2 2026: revenue $802M (+24% year over year), operating margin 16.2%, net earnings $95.0M, operating cash flow $88.4M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 70.2% | 69.7% | +0.5 pts |
| Operating margin | 16.2% | 18.7% | -2.5 pts |
| Net margin | 11.8% | 3.5% | +8.4 pts |
| Free cash flow margin | 7.0% | 27.4% | -20.4 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| U.S. | $544M | $453M | $90.9M | +20% |
| International | $252M | $186M | $66.0M | +36% |
| Total Omnipod products | $796M | $639M | $157M | +25% |
| Drug Delivery | $5.8M | $10.2M | −$4.4M | -43% |
| Revenue | $802M | $649M | $153M | +24% |
| Gross profit | $563M | $452M | $110M | +24% |
| Cost of revenue | $239M | $197M | $42.2M | +21% |
| Operating profit | $130M | $121M | $8.6M | +7% |
| Operating expenses | $433M | $331M | $102M | +31% |
| Pre-tax earnings | $119M | $28.4M | $90.3M | +318% |
| Other expense, net | $11.0M | $92.7M | −$81.7M | -88% |
| Research & development | $88.1M | $73.4M | $14.7M | +20% |
| SG&A | $345M | $258M | $87.1M | +34% |
| Net earnings | $95.0M | $22.5M | $72.5M | +322% |
| Income tax | $23.7M | $5.9M | $17.8M | +302% |
| Depreciation & amortization | $26.7M | $22.3M | $4.4M | +20% |
| Share-based compensation | $19.6M | $7.5M | $12.1M | +161% |
| Working capital & other | $52.9M | −$144M | $197M | — |
| Operating cash flow | $88.4M | $196M | −$108M | -55% |
| Free cash flow (OCF − capex) | $55.9M | $178M | −$122M | -69% |
| Capital expenditures | $32.5M | $18.6M | $13.9M | +75% |
Questions
How much did Insulet's revenue grow year over year in Q2 2026?
Insulet's revenue rose $153M (+24%) from $649M in Q2 2025 to $802M in Q2 2026.
What drove Insulet's revenue change in Q2 2026?
Total Omnipod products +$157M (+25%); Drug Delivery −$4.4M (-43%).